Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion

Journal of Pharmacology and Experimental Therapeutics

Volumn 297, Issue 2, 2001, Pages 496-500

  Quinn, Martin J ^a   Murphy, Ross T ^b   Dooley, Michelle ^a   Foley, J Brendan ^b   Fitzgerald, Desmond J ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR;

ADULT; AGED; ANALYZER; ANTIGEN BINDING; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; DRUG INFUSION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOASSAY; MALE; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0035028123     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade
2. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: Importance of internal pool of glycoprotein IIb-IIIa receptors
3. Free and total platelet glycoprotein IIb/IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA
4. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
5. Distribution of ligand-occupied alpha IIb beta 3 in resting and activated human platelets determined by expression of a novel class of ligand-induced binding site recognized by monoclonal antibody AP6
6. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): Flow and endocytic mechanisms contribute to the transport
7. Quantifying GPIIb/IIIa receptor binding using two monoclonal antibodies. Discriminating abciximab and small molecular weight antagonists
8. Dose and duration dependence of aspirin-induced augmentation of inhibition of fibrinogen binding by ReoPro (Abstract)
9. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
10. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
11. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
12. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
13. Platelet GPIIb-IIIa blockers
14. Platelet GPIIb/IIIa receptor occupancy studies using a novel fluoresceinated cyclic Arg-Gly-Asp peptide
15. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets